<DOC>
	<DOC>NCT03001115</DOC>
	<brief_summary>The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.</brief_summary>
	<brief_title>Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participant who are eligible to be treated with adalimumab for HS in accordance with the approved Korean label Participant must provide written authorization form to use their personal health data prior to the participating in the study. Participant who are contraindications to adalimumab as listed on the approved Korean label. Participant who is participating on other clinical trials.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Korean participants</keyword>
	<keyword>Hidradenitis Suppurativa</keyword>
	<keyword>Safety</keyword>
	<keyword>Adalimumab</keyword>
</DOC>